Therapy Detail

Therapy Name JNJ-61610588
Therapy Description

JNJ-61610588 is an immune checkpoint inhibitor and monoclonal antibody that targets the T-cell receptor, VISTA (PD1H), V-type immunoglobulin domain-containing suppressor of T-cell activation, to evoke an anti-tumor response (NCI Drug Dictionary).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
JNJ-61610588 JNJ 61610588 Immune Checkpoint Inhibitor 99 JNJ-61610588 is an immune checkpoint inhibitor and monoclonal antibody that targets the T-cell receptor, VISTA (PD1H), V-type immunoglobulin domain-containing suppressor of T-cell activation, to evoke an anti-tumor response (NCI Drug Dictionary).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Clinical Trial Phase Therapies Title Recruitment Status
NCT02671955 Phase I JNJ-61610588 A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer Terminated